This edition first published 2022 © 2022 John Wiley & Sons, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions. The right of Andrew Teasdale to be identified as the author of the editorial material in this work has been asserted in accordance with law. Registered Office John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA Editorial Office 111 River Street, Hoboken, NJ 07030, USA For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com. Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats. Limit of Liability/Disclaimer of Warranty In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data Applied for:
[hardback isbn 9781119551218] Cover Design: Wiley Cover Image: © theasis/GettyImages
Preface Since the advent of the first book specifically focused on genotoxic (mutagenic) impurities that I authored and was released in 2010, a considerable amount of progress has been made in terms of management of such impurities. Indeed many of the concepts defined for the first time within the book have ultimately become enshrined in standard practice relating to mutagenic impurities. These include how to conduct a risk assessment, the use of SAR evaluation tools, compound‐specific limits, and the use of purge factors to assess carryover risk, to name a few. Indeed most if not all were ultimately captured within ICH M7, which was formalized in 2014. As a result of this and continued advancement of the science pertaining to many of these and other concepts, it seemed timely to seek to update the book. Little did I or others foresee at the point where this was proposed the dramatic impact of N‐nitrosamines. By necessity, the book seeks to address not only the changes in general around management of mutagenic impurities, it also seeks to outline a holistic approach to management and control of N‐nitrosamines, covering all aspects of their management from a safety and quality perspective. As well as this new chapter has been added specifically seeking to examine side reactions that can result in mutagenic impurities, dramatically expanding on the work in the first book that was focused simply on sulfonate esters.
1 Historical Perspective on the Development of the EMEA Guideline and Subsequent ICH M7 Guideline 1.1 Introduction To enable a thorough understanding of the current regulatory position relating to mutagenic impurities (regularly referred to as genotoxic impurities initially) as defined by ICH M7 [1], it is first important to consider the history behind the events that led up to this point and their context. Like many events, the exact point at which concerns relating to the potential presence of mutagenic impurities (MIs) in pharmaceuticals first emerged is difficult to determine. At the time that ICH Q3 guidelines were constructed, specifically ICH Q3A [2], only passing reference was made to compounds of “unusual toxicity” and the potential need for limits tighter than those defined by the guidelines. Although the term “genotoxic” or indeed “mutagenic” is not specifically mentioned, many have taken this to refer to impurities that are mutagenic. The first public evidence of specific regulatory concern relating to genotoxic impurities was an article published within PharmEuropa in 2000 [3], which drew attention to the potential risk of formation of sulfonate esters resulting from the combination of sulfonic acids in alcoholic solution as part of a salt formation process. At this point this publication was merely a call for “further information,” it being part of an attempt to better understand the extent of any risk involved. The publication is now seen as a landmark event, signaling a new era of focus on genotoxic impurity risk assessment and control. It is interesting to reflect on the irony that the “start point” should indeed be sulfonate esters given the long‐standing concerns and investigations performed relating to such potential impurities over the subsequent years, much of which are described throughout the chapters within this book. The first real attempt to generate some form of regulatory framework pertaining to MIs was a position paper relating to genotoxic impurities (GIs) published by the Committee for Proprietary Medicinal Products (CPMP1) on behalf of the European Medicines Agency (EMA) Safety Working Party (SWP) for comments in December 2002 [2]. Outlined below is an evaluation of this first draft position paper and an assessment of its later significance in the context of the finalized ICH M7 guideline. 1.1.1 CPMP – Position Paper on the Limits of Genotoxic Impurities –2002 1.1.1.1 Scope/Introduction Within the introduction to the position paper, it was made clear that the need for such guidance was due to the fact that control over levels of genotoxic residues was not adequately addressed through existing ICH guidance. The position paper consists of a series of sections that addressed the issue of genotoxic
